interstitial nephritis and cardiomyopathy in a patient recently started on clozapine.
A healthy 26-year-old man with bipolar-type schizoaffective disorder presented with bizarre, threatening behaviour and paranoid hallucinations. He was started on valproic acid, lithium, risperidone and clonazepam. Minimal improvement was noted, and after 8 weeks he was gradually switched from risperidone to 125 mg of clozapine. At this point all his blood work was normal and he had good exercise tolerance. After 2 weeks of initiating clozapine, he was transferred to our hospital for a fever of 104.2 F. On admission he was found to be hypertensive (BP 167/107) and tachycardiac. His physical exam was unremarkable, without any signs of fluid overload. He had an elevated serum creatinine (1.5 mg/dl) and WBC (13 000/mm 3 ) with peripheral eosinophilia (820/mm 3 ). His urinalysis showed 2+ protein, 5-10 white cell casts and >50 WBC with significant eosinophiluria. Chest X-ray and urine, blood and CSF cultures were negative. All medications were stopped, and he was given intravenous hydration. Intravenous steroids were started for presumed clozapine-induced interstitial nephritis. On Day 6, his creatinine peaked to 5 mg/dl. He maintained good urine output throughout his stay. A renal biopsy was scheduled but was cancelled because of subsequent complicated course and improving renal function thereafter.
On Day 8 he developed dyspnea and bilateral inspiratory rales. He denied chest pain. Chest X-ray and CT-scan were consistent with pulmonary oedema. His pro-BNP was 27 727 pg/ml. EKG and cardiac enzymes remained normal and viral titers were negative. He was started on intravenous diuretics. An echocardiogram showed moderate global left ventricular dysfunction with an EF of 40% and left ventricular diastolic internal dimension of 5 cm. Next day, he was intubated for respiratory distress from CHF and was transferred to ICU. His respiratory status gradually improved with diuresis and he was extubated after 3 days. Beta-blockers, hydralazine and nitrates were initiated for CHF. At discharge, his eosinophilia resolved, creatinine was 1.36 mg/dl and pro-BNP was 812 pg/ml. Two weeks later, an echocardiogram showed some recovery (EF 50%).
The patient's previous tolerance of all other medications, the chronological onset of his symptoms after initiating clozapine and the fact that there was no previous cardiac history suggest that this case most likely represents clozapine-induced acute interstitial nephritis and cardiomyopathy. While dilated cardiomyopathy is more common with clozapine, a third of patients develop non-dilated cardiomyopathy [5] , as seen in our patient. Both the processes are probably related to IgE-mediated hypersensitivity reaction, and hence the simultaneous occurrence is not surprising [1, 3, 5] . To the best of our knowledge, this is the first case of simultaneous clozapine-induced interstitial nephritis and cardiomyopathy. Clozapine maybe associated with fatal complications in healthy young adults and it is imperative that physicians are aware of these potentially lethal side effects. 
Sorafenib treatment and intracaval neoplastic thrombosis regression
Sir, Up to 10% of patients with renal clear cell carcinoma (RCC) have intracaval neoplastic extension (ICNE). Caval thrombectomy is associated with a 7.5% early mortality and requires a multidisciplinary surgical team, with the use of cardiopulmonary bypass (CPB). Furthermore, this surgical option has not revealed any substantial impact on the long-term survival of patients [1] . We report a favourable outcome of recurrent ICNE under sorafenib treatment, in a patient who had previously undergone surgery.
A 62-year-old man was diagnosed in May 2006 with ICNE secondary to left RCC. He underwent a nephrectomy and removal of intracaval thrombosis extending into the right atrium. Postoperative serum creatinine level was 1.70 mg/dL. Pathological exam confirmed the neoplastic nature of the thrombus related to RCC. Despite thrombolytic agents followed by anticoagulant treatment, ICNE recurred 2 months later, with right renal vena extension inducing oliguric acute renal failure (serum creatinine, 7.38 mg/dL), and required iterative haemodialysis. Despite a 5-month compassionate use of sunitinib 37.5 mg daily and maintained anticoagulation, ICNE remained stable ( Figure 1A ) and the patient remained haemodialysis dependent. In January 2007, he was then treated with sorafenib 400 mg twice a day. Three months after the start of the treatment, his pre-haemodialysis serum creatinine level decreased from 5.63 to 1.77 mg/dL, and he became free of dialysis up to the present. Magnetic resonance nuclear imaging revealed a reduction of the thrombus mass ( Figure 1B ) compared to the pre-sorafenib treatment: the transversal diameter of the caval and renal veins, from 32 to 22 mm and from 22 to 18 mm, respectively.
In our patient, sorafenib-induced thrombus regression suggests a role for angiogenesis in this process. Indeed, activation of intracellular signalling (phosphoinositol 3P, Ras/Raf kinase and MAP kinase) pathways mediated by the expression of tissue factor, a thrombotic key factor, has been linked to tumour progression [2, 3] . Because oncogenic activation of the Ras/Raf pathway may lead to a sustained proliferative signal resulting in tumour growth and progression, inhibition of this pathway may represent an attractive approach for ICNE treatment. Furthermore, vascular endothelial growth factor (VEGF) was found to be increased after retinal vein occlusion [4] and intra-vitreal injection of bevacizumab, an anti-VEGF antibody, can improve visual acuity in those patients. In analogy to this condition, we hypothesized that in our patient, sorafenib, an orally active multi-kinase inhibitor, initially identified as a Raf kinase inhibitor, might have induced the partial resolution of venous thrombus and its extension in the renal vein, thus leading to renal function recovery. To address this issue, we chose subjects of ESRD caused by DM or chronic glomerulonephritis (CGN) (as a control) receiving haemodialysis, and measured their serum PSA concentrations. The mean age, a risk factor of prostate cancer, was no different between the two groups ( Table 1) . The haemodialysis duration was twice as long in the CGN group (Table 1) , but was unrelated to PSA levels in both groups when examined by Spearman's correlation coefficient obtained using the rank test. The PSA levels were significantly lower in the DM group compared to those in the CGN group (Table 1) . This is in agreement with previous results showing that the PSA levels of DM patients were low in subjects without ESRD [4] . The PSA levels of the DM or CGN group were similar to those of healthy volunteers (1.63 ± 0.13 ng/ml) and ESRD patients (2.18 ± 0.12 ng/ml), respectively [2] . This indicates that PSA levels of ESRD DM patients are slightly lower than those of healthy volunteers, and that the PSA levels of CGN are representatives for the ESRD population. The prevalence of prostate cancer was not significantly different between the two groups, yet there is a tendency for a decreased number of patients with PSA values >4 ng/ml in the DM group, in comparison with the CGN group ( Table 1 ). The levels of testosterone associated with increased prostate cancer risk, and those of insulin that promotes prostate cancer cell growth, are lower in DM patients [5] ; these factors remain at lower levels after the patients advance to ESRD, which may explain low PSA levels in the DM group.
Our results suggest that DM is associated with decreased PSA levels, and likely of prostate cancer risk, irrespective of the complication of ESRD. These results support an inverse relationship between DM and prostate cancer.
